hrs4r
 I want to donate
Main lines of research

-Intersection between sleep diseases, cardiovascular risk, senescence and ageing.
-Development of early diagnosis methods for lung cancer.
-Study of the links between COVID-19, cardiovascular risk and COVID persistence.
-Research on respiratory diseases and intestinal dysbiosis with special attention to the lung-gut axis.
-Analysis of pulmonary hypertension, pulmonary embolism and endothelial dysfunction.
-Identification of biomarkers in cardiopulmonary diseases.
-Implementation of 2D and 3D vascular models, organ-on-a-chip and animal models to deepen the understanding of the underlying mechanisms.

Strategic objectives

Sleep Disorders and Cardiovascular Risk, Senescence and Ageing:

-Investigate the molecular relationships between sleep diseases and the development of cardiovascular problems.

-Identify possible treatments to mitigate the effects of poor sleep on the senescence process.

Early diagnosis of lung cancer:

- Develop new early detection technologies with the aim of improving survival rates in lung cancer patients.

COVID-19, Cardiovascular Risk and Persistent COVID:

-Investigate the mechanisms linking COVID-19 infection with cardiovascular risk. Compare with other respiratory viruses

Understand the persistence of COVID and its long-term effects on cardiovascular health.

Respiratory Diseases and Intestinal Dysbiosis (Lung-Gut Axis):

-Exploring the molecular interactions between the respiratory system and the gut microbiota to better understand dysbiosis and its impact on respiratory diseases.

Pulmonary Hypertension, Pulmonary Embolism and Endothelial Dysfunction:

-Investigate the pathophysiological mechanisms of pulmonary hypertension and pulmonary embolism.

-To develop therapeutic strategies aimed at improving the associated endothelial dysfunction.

Study of Biomarkers in Cardiopulmonary Diseases:

-Identify and validate specific biomarkers for different cardiopulmonary diseases.

-Establish standardised protocols for the clinical use of the identified biomarkers.

2D and 3D Vascular Models, Organ-on-a-Chip and Animal Models:

-Optimise and validate in vitro vascular models for preclinical studies.

-To integrate the different models to obtain a more complete view of the physiopathological processes in cardiopulmonary diseases.

Publications
Poyatos P, Luque N, Sabater G, Eizaguirre S, Bonnin M, Orriols R, Tura-Ceide O

Endothelial dysfunction and cardiovascular risk in post-COVID-19 patients after 6-and 12-months SARS-CoV-2 infection

Infection, 2024 dx.doi.org/10.1007/s15010-024-02173-5
Orriols R, Torrente A, Campà MT, Comas-Cufí M, Tura-Ceide O, Sabater G, Vendrell M

Artificial Stone Silicosis. Progression and Laboral Impact After 3-years Follow-up.

ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59, 267-269 dx.doi.org/10.1016/j.arbres.2022.11.008
Ayyoub S, Orriols R, Oliver E, Ceide OT

Thrombosis Models: An Overview of Common In Vivo and In Vitro Models of Thrombosis

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 dx.doi.org/10.3390/ijms24032569
Eichstaedt CA, Belge C, Chung WK, Gräf S, Grünig E, Montani D, Quarck R, Tenorio-Castano JA, Soubrier F, Trembath RC, Morrell NW

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

EUROPEAN RESPIRATORY JOURNAL, 2023, 61 dx.doi.org/10.1183/13993003.01471-2022
Peinado VI, Guitart M, Blanco I, Tura-Ceide O, Paul T, Barberà JA, Barreiro E

Atrophy signaling pathways in respiratory and limb muscles of guinea pigs exposed to chronic cigarette smoke: role of soluble guanylate cyclase stimulation

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2023, 324, 677-693 dx.doi.org/10.1152/ajplung.00258.2022
Ayyoub S, Blanco I, Izquierdo-García JL, Tura-Ceide O

Metabolic changes in vascular disorders: A path for early diagnosis and new therapeutic targets

Frontiers In Cardiovascular Medicine, 2023, 10, 1163298-1163298 dx.doi.org/10.3389/fcvm.2023.1163298
Poyatos P, Gratacós M, Samuel K, Orriols R, Tura-Ceide O

Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension

Antioxidants, 2023, 12 dx.doi.org/10.3390/antiox12051006
Blanco I, Marquina M, Tura-Ceide O, Ferrer E, Ramírez AM, Lopez-Meseguer M, Callejo M, Perez-Vizcaino F, Peinado VI, Barberà JA

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

FRONTIERS IN PHARMACOLOGY, 2023, 14, 1145994-1145994 dx.doi.org/10.3389/fphar.2023.1145994
Roth L, Dogan S, Tuna BG, Aranyi T, Benitez S, Borrell-Pages M, Bozaykut P, De Meyer GRY, Duca L, Durmus N, Fonseca D, Fraenkel E, Gillery P, Giudici A, Jaisson S, Johansson M, Julve J, Lucas-Herald AK, Martinet W, Maurice P, McDonnell B, Ozbek EN, Pucci G, Pugh CJA, Rochfort KD, Roks AJM, Rotllan N, Shadiow J, Sohrabi Y, Spronck B, Szeri F, Terentes-Printzios D, Aydin ET, Tura-Ceide O, Ucar E, Anacak GY

Pharmacological modulation of vascular ageing: A review from VascAgeNet

AGEING RESEARCH REVIEWS, 2023, 92, 102122-102122 dx.doi.org/10.1016/j.arr.2023.102122
Zodda E, Tura-Ceide O, Mills NL, Tarragó-Celada J, Carini M, Thomson TM, Cascante M

Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction

eLife, 2023, 12 dx.doi.org/10.7554/eLife.86260
Competitive projects
Codi oficial: PI21/01212- SIENA Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: 2022 FI_B 00941 Start date:01/06/2022 Data fi: 31/05/2025 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA (AGAUR)
Codi oficial: 907/2019 Start date:28/12/2021 Data fi: 31/12/2024 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: SOCIEDAD ESPAÑOLA NEUMOLOGIA Y CIRUGIA TORACICA (SEPAR)
Codi oficial: 1087 Start date:28/12/2021 Data fi: 31/12/2024 Investigador/a principal: OLGA TURA CEIDE, OLGA TURA CEIDE Organisme finançador: SOCIEDAD ESPAÑOLA NEUMOLOGIA Y CIRUGIA TORACICA (SEPAR)
Codi oficial: CPII22/00006 Start date:01/06/2023 Data fi: 31/05/2026 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: FI22/00133 Miriam Peracaula Start date:01/01/2023 Data fi: 31/12/2026 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: 202336-30 Start date:01/01/2024 Data fi: 31/12/2026 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: FUNDACIO LA MARATO TV3
Codi oficial: 2023_SEC_OTC Start date:16/06/2023 Data fi: 31/12/2027 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: SOCIEDAD ESPAÑOLA DE CARDIOLOGIA
Codi oficial: CNS2023-145362 Start date:01/04/2024 Data fi: 30/06/2026 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO /
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu